HOME >> BIOLOGY >> NEWS
Paratek Pharmaceuticals presents multiple sclerosis data at Society for Neuroscience annual meeting

Paratek Pharmaceuticals, Inc. announced results of preclinical studies demonstrating that a new class of compounds, orally available non-antibacterial tetracyclines, has shown promising activity in a preclinical animal model of multiple sclerosis (MS). Affecting approximately two million people worldwide, MS is a chronic, inflammatory condition of the nervous system and the most common, non-traumatic, neurological disease in young adults. Dr. David McKenney, a Paratek scientist, will present the findings during an oral presentation at 2:30 p.m. PST (5:30 p.m. EST) today at Neuroscience 2004, the Society for Neuroscience's 34th Annual Meeting in San Diego.

For the first time, Paratek is presenting data showing that its non-antibacterial tetracycline compounds in a preclinical model of MS have efficacy comparable to minocycline, an antibiotic also in the tetracycline family. A previous clinical study directed by Dr. Luanne Metz at the University of Calgary has demonstrated disease protection in MS patients treated with minocycline. Unfortunately, long-term treatment with minocycline or any other broad-spectrum antibiotics causes many patients to experience intolerability related to antibiotic side effects. In today's presentation, Paratek will report that three non-antibacterial tetracycline compounds, with different structures, demonstrated activity in reducing limb paralysis in the preclinical EAE (Experimental Autoimmune Encephalomyelitis) model of MS. These compounds have no detectable antibacterial activity.

Paratek Pharmaceuticals, Inc. and Serono (virt-x: SEO and NYSE: SRA) announced today that they have entered into an agreement to discover, develop and commercialize an orally-available disease modifying treatment for multiple sclerosis (MS). The agreement covers the compounds for which Dr. McKenney presents data today.

Stuart Levy, Paratek's Vice Chairman, Chief Scientific Officer and Co-Founder, commented, "The clinica
'"/>

Contact: Katie Compa
kcompa@burnsmc.com
212-213-0006
Burns McClellan
27-Oct-2004


Page: 1 2

Related biology news :

1. Scientists at Galileo Pharmaceuticals confirm inflammatory response linked to glucose levels
2. Progenika Biopharma presents a biochip that guarantees safety in blood transfusions
3. SNM presents awards on Capitol Hill
4. ESA presents the sharpest ever satellite map of Earth
5. New book presents neurobiology from an evolutionary perspective
6. Lighting up life: Cold Spring Harbor Protocols presents tips for creating glowing plants
7. Childrens Hospital and Research Center-Oakland presents a new maternal diet study
8. USGS presents a world of science at GSA in Philadelphia
9. Childrens Hospital Boston presents at the 2006 American Academy of Pediatrics National Conference
10. DFG presents the 2006 MAK and BAT value list
11. Childrens Hospital Boston presents at the 2006 Pediatric Academic Societies annual meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):
(Date:8/16/2017)... ... 2017 , ... Today, 3Bar Biologics Inc ., the ... funding from an impressive group of investors, including Rev1 Ventures, Maumee Ventures, Ohio ... investment, 3Bar is broadening availability of its groundbreaking offering that uses naturally occurring ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art ... GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma ... and data collection vis a vis their members, under their own ... of this offer. ... ...
(Date:8/15/2017)... ... 2017 , ... Any expert in stem cell research or stem cell medicine ... half a century. Despite their essential roles in human health and regenerative medicine, ... tags developed for this purpose also tag other, more abundant, non-stem tissue cells ( ...
(Date:8/15/2017)... ... August 15, 2017 , ... JULABO USA introduces ... the new website makes it easy to navigate through the site whether you’re ... find detailed product information, educational industry content and visit the company’s social media ...
Breaking Biology Technology:
Cached News: